Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.
Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future
Date:
More like thisRelated
‘She’s One of Us’: Mary Peltola’s Bumpy Rise to Political Power
Ms. Peltola, the Democratic Senate candidate in Alaska, has...
A ‘Big Problem’: Trump’s War With Iran Drags Down Republicans in Midterms
As their November picture darkens, and gas and diesel...
Dogs Will Fight Bears. But Not Because of the Reason You Might Think.
Scientists analyzed hundreds of encounters between bears and canines....